MedTrace Logo

Efficacy and Safety of Ostenil® Plus in the Treatment of Coxarthrosis

NCT03809962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2025-06-05

No results posted yet for this study

Summary

PMCF study to observe the Routine application of Ostenil® Plus in the Treatment of pain and restricted mobility in degenerative and traumatic changes of the Hip Joint.

Conditions

  • Coxarthrosis

Interventions

DEVICE

Ostenil® Plus

Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation

Sponsors & Collaborators

  • TRB Chemedica AG

    lead INDUSTRY

Principal Investigators

  • Knut Behle, Dr. med. · OrthopädieZentrum Maschen

  • Darja Becker, Dr. med. · Orthopädie Praxis Dr. Darja Becker

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2025-05-14
Completion
2025-05-14

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03809962 on ClinicalTrials.gov